【Research Projects】
[1] State Administration for Market Regulation, The International Experience in Drug Safety Supervision, May-December, 2019
[2] National Medical Products Administration, Research on Administrative Measures for Domestic Agents of Overseas Drug Marketing Authorization Holders, October - December, 2021.
[3] Bill and Melinda Gates Foundation, Regulatory Science Think Tank Construction of Vaccines and Other Medical Products, November 2019 - December 2021
[4] Beijing ADPAC International Consulting Co., Ltd., Policy Progress and Outlook of Pharmaceutical Intellectual Property Rights Protection in China, September - December, 2021
[5] China Society for Drug Regulation, Study on Reference of PDUFA Act for Capacity Improvement of Drug Regulators, October - November, 2021
[6] China Society for Drug Regulation, Study on the Revision of Prescription and OTC Drugs Classified Administrative Measures, September 2021 - August 2022
[7] Shanghai Johnson & Johnson Pharmaceutical Co., Ltd., Implementation Progress and Problems of the Marketing Authorization Holder System, November 2021 - May 2022
[8] Beijing Drug Administration, “Drug Safety Supervision in Beijing (2020)” and “Study on Drug Safety Risks and Countermeasures in Beijing”, September - December 2021
[9] China Center for Food and Drug International Exchange, Study on the Bench-marking Issues and Promotion Strategies for Chinese Drug Regulators’ Joining the PIC/S Inspection List, August 2021 - September 2022
[10] China Center for Food and Drug International Exchange, Study on the Concept and Methodology of the Design Guidelines of the ICH E20 Adaptive Clinical Tests, August 2021 - September 2022
[11] Drug Administration of Guangxi Zhuang Autonomous Region, Study on Medical Product Regulatory System of ASEAN Countries, November 2021 - December 2022
[12] Beijing ADPAC International Consulting Co., Ltd., Study on the Relationship between New Drug Definition and Related Systems under the Background of Pharmaceutical Power, December 2021 - April 2022
【Academic Achievements】
[1] Li Xiaoyu,Yang Yue. The drug lag issue: a 20-year review of China.[J]. Investigational new drugs, 2021，4,30，10.1007/s10637-021-01117-2 （IF= 3.850）
[2] Mao, X.,Yang, Y*.Gap analysis for chinese drug control institutes to achieve the standards of world health organization medicine prequalification. Journal of Pharmaceutical Sciences. 2017, 106（2）: 652-659（IF 3.075）
[3] Aslam F, Yue Y*, Aziz M. Introduction of typhoid vaccine in the expanded immunization program of Pakistan. Hum Vaccin Immunother. 2021 Jul 3;17(7):2132. doi: 10.1080/21645515.2020.1869496. Epub 2021 Jan 31. PMID: 33522429; PMCID: PMC8189075.
[4] Aslam F, Khan FU, Yue Y. Rational Prescription and Cost-Effective Medication: Challenges and Opportunities in Pakistan. Innov Pharm. 2020 Oct 22;11(4):10.24926/iip.v11i4.1613. doi: 10.24926/iip.v11i4.1613. PMID: 34007642; PMCID: PMC8127104.
[5] Guo, T.,Yang Y., et al. Effects of midodrine in patients with ascites due to cirrhosis: systematic review and meta-analysis. Journal of Digestive Diseases. 2016, 17 (1) :11-19（SCI IF1.623）
【Enrollment Majors】 Biomedical engineering
【Contact Information】yanghappy@tsinghua.edu.cn
Post-doctors related with regulatory science are recruited all year round. Those with English proficiency will be preferred.
